Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Enzon Pharmaceuticals Inc (ENZN)

Enzon Pharmaceuticals Inc (ENZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 5,789
  • Shares Outstanding, K 74,220
  • Annual Sales, $ 0 K
  • Annual Income, $ 1,370 K
  • 60-Month Beta 0.33
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.95
Trade ENZN with:
  • Price/Earnings ttm 7.24
  • Earnings Per Share ttm 0.01
  • Most Recent Earnings $0.01 on 03/20/24
  • Latest Earnings Date 05/03/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend 0.240 on 09/30/19
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0600 +30.00%
on 04/01/24
0.0997 -21.77%
on 04/09/24
+0.0080 (+11.43%)
since 03/22/24
3-Month
0.0600 +30.00%
on 04/01/24
0.1058 -26.28%
on 01/26/24
-0.0106 (-11.96%)
since 01/22/24
52-Week
0.0600 +30.00%
on 04/01/24
0.2298 -66.06%
on 04/25/23
-0.1370 (-63.72%)
since 04/20/23

Most Recent Stories

More News
Enzon Pharmaceuticals, Inc. CEO Andrew Rackear to Retire; Richard L. Feinstein, Enzon’s CFO, to Assume Position of CEO and Remain CFO

CRANFORD, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTC:ENZN) announced today that Andrew Rackear has communicated to the Board his intent to retire from his role as the Company’s...

ENZN : 0.0780 (+7.73%)
Enzon Pharmaceuticals Announces Results of Rights Offering

Looking to Next Step – Acquisition Opportunities

ENZN : 0.0780 (+7.73%)
Enzon Pharmaceuticals Announces Key Dates for Rights Offering

CRANFORD, N.J., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) announced today the record date and expected subscription period for its previously-announced...

ENZN : 0.0780 (+7.73%)
Enzon Pharmaceuticals, Inc. Announces Postponement of 2020 Annual Meeting

CRANFORD, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) today announced that its 2020 annual meeting of stockholders (the “Annual...

ENZN : 0.0780 (+7.73%)
Enzon Pharmaceuticals Anticipated Rights Offering to Existing Shareholders

CRANFORD, N.J., Aug. 21, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC: ENZN) today announced that its Board of Directors (the “Board”) has approved...

ENZN : 0.0780 (+7.73%)
Enzon Pharmaceuticals, Inc. Adopts Tax Benefits Preservation Plan to Protect its NOL Assets and Shareholder Value

CRANFORD, N.J., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) today announced that its Board of Directors (the “Board”) adopted a tax...

ENZN : 0.0780 (+7.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Enzon Pharmaceuticals, Inc. is a biotechnology company. It discovers, develops, and commercializes therapeutics to treat life-threatening diseases. The Company's marketed drug products include PegIntron (R) for chronic hepatitis C; Sylatron (R) for Melanoma; Macugen (R) for neovascular age-related macular...

See More

Key Turning Points

3rd Resistance Point 0.0780
2nd Resistance Point 0.0780
1st Resistance Point 0.0780
Last Price 0.0780
1st Support Level 0.0780
2nd Support Level 0.0780
3rd Support Level 0.0780

See More

52-Week High 0.2298
Fibonacci 61.8% 0.1649
Fibonacci 50% 0.1449
Fibonacci 38.2% 0.1249
Last Price 0.0780
52-Week Low 0.0600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar